πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 87 of 173

  1. US 9409944

    Compositions and methods for inhibiting proteases

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9408813

    Small-molecule inhibitors of dengue virus proteases

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9403908

    Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9403856

    Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9403815

    Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9403800

    Compounds for inhibition of cancer cell proliferation

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9403778

    Agents that prevent or repair skin damage

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9402911

    Multifunctional small molecules

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9402850

    BAX agonist, compositions, and methods related thereto

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9402876

    Method and pharmaceutical composition for hair growth

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9402881

    Tissue regeneration and wound treatment methods with platelet derived compositions

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9403911

    Compositions and methods for detection and treatment of cancer

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9399666

    Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9399627

    Substituted macrocyclic compounds having proteasome inhibitory activity

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9399662

    Concurrent chemotherapy and immunotherapy

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9394541

    Oral delivery of nucleic acid-based gene interfering agents by Salmonella

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9394369

    Luminescent porous silicon nanoparticles for targeted delivery and immunization

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9394303

    Small molecule inhibitors of MCL-1 and uses thereof

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9394338

    Glutathione analogs and uses thereof

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9394241

    Composition and method for making oligo-benzamide compounds

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9393306

    Singlet oxygen-labile linkers and methods of production and use thereof

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9393285

    Compositions for treating dry eye disease

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9393257

    TALEN-based gene correction

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9394343

    Appetite stimulating protein

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9395369

    Guinea pig cytomegalovirus (CIDMTR strain)

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9387217

    Acyclic nucleoside phosphonate diesters

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9388244

    Internalizing ErbB2 antibodies

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9388247

    Antibodies against cancer target block tumor growth, angiogenesis and metastatis

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9388218

    PRRSV compositions

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9388159

    Substituted diazaspiroalkanes as androgen receptor modulators

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9387245

    Methods and compositions for the inhibition of fructokinase

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9388163

    Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9381185

    Methods of inducing sedation

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9381236

    Interferon-Ξ² production modulating listeria strains and methods for using same

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9382230

    Methods and compositions for modulating Ire1, SRC and ABL activity

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9375484

    Taxane silicate prodrugs and nanoparticles

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9376481

    Methods of promoting CNS neuronal repair by inhibiting LRP-1

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9375475

    Combination immunotherapy for the treatment of cancer

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9375313

    Intramyocardial patterning for global cardiac resizing and reshaping

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9371516

    Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9370514

    Methods for fine particle manufacture

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9372186

    Minimally-invasive measurement of esophageal inflammation

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9370521

    Targeting GLI proteins in human cancer by small molecules

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9371337

    Ξ²-lactamase inhibitors

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9370527

    Amelioration of intestinal fibrosis and treatment of Crohn's disease

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9364462

    Alpha-1-adrenergic receptor agonist therapy

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9364563

    Methods and compositions for liposomal formulation of antigens and uses thereof

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9364535

    Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.